Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 8945 - 8952 of 12092 results
When Transparency Is Not Enough: Class Action Litigation Under California's Transparency in Supply Chains Act
November 12, 2015| Blog| Viewpoint
Court Orders Plaintiffs to Pay Defendants' $13.3 Million Appellate Costs in Lawrence E. Jaffe Pension Plan v. Household International
November 12, 2015| Blog| Viewpoint
Breaking News: DOL Indicates That New White Collar Exemption Overtime Rule May Not Go Into Effect Until Late 2016
November 12, 2015| Blog| Viewpoint
FDA Requests Input on Use of the Term “Natural” for Foods
November 11, 2015| Blog| Viewpoint
Corporate Counsel: Circuit Court Backs NLRB on Social Media Conduct, Voids Handbook Provision
November 11, 2015| Blog| Viewpoint
NYT: Many Low-Income Workers Say ‘No’ to Health Insurance
November 11, 2015| Blog| Viewpoint
PTAB May Allow a Petitioner to Correct An Improper IPR Reply Brief
November 11, 2015| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|